PMC:7536954 / 3541-3709 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7536954","sourcedb":"PMC","sourceid":"7536954","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7536954","text":"e resolution of COVID‐19 symptoms and resulted negative. Thus, secukinumab therapy was reintroduced after 8 weeks from the last administration.\nManagement of moderate t","tracks":[{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T47","span":{"begin":16,"end":24},"obj":"Disease"}],"attributes":[{"id":"A47","pred":"mondo_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"subj":"T47","pred":"source","obj":"LitCovid-PD-MONDO"}]},{"project":"LitCovid-PubTator","denotations":[{"id":"123","span":{"begin":63,"end":74},"obj":"Chemical"},{"id":"137","span":{"begin":16,"end":24},"obj":"Disease"}],"attributes":[{"id":"A123","pred":"tao:has_database_id","subj":"123","obj":"MESH:C555450"},{"id":"A137","pred":"tao:has_database_id","subj":"137","obj":"MESH:C000657245"},{"subj":"123","pred":"source","obj":"LitCovid-PubTator"},{"subj":"137","pred":"source","obj":"LitCovid-PubTator"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}]},{"project":"LitCovid-sentences","denotations":[{"id":"T34","span":{"begin":57,"end":143},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T34","pred":"source","obj":"LitCovid-sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-PD-MONDO","color":"#ece393","default":true},{"id":"LitCovid-PubTator","color":"#c993ec"},{"id":"LitCovid-sentences","color":"#93ecaf"}]}]}}